

prior authorization (PA) checklist for Aimovig™ (erenumab-aooe)

a resource to help you organize common PA considerations
and potential requirements

Healthcare provider (HCP) name _____ Neurology/Headache specialist? Yes No

If no, has a specialist been consulted? Yes No

Patient name _____ Date of birth ____/____/____

Patient insurance plan _____

Diagnosis

1 Average number of headache days of any kind experienced per month over the past 3 months _____
– To help clarify the number of headache days experienced per month, you may also ask for the number of days per month completely free of headaches

2 Average number of migraine days per month _____

If **15+** headache days, with **≥8** migraine days, diagnosis = **Chronic migraine***
If **<15** headache days, with **4+** migraine days, diagnosis = **Episodic migraine***

Treatment

3 Is Aimovig™ being prescribed to prevent migraine? Yes No

4 Has patient taken an acute migraine medication (eg, triptan)? Yes No
If yes, was this within the past 3 months? Yes No If no, was patient intolerant of triptans? Yes No

5 Has patient tried preventive medications (eg, antidepressants, antiepileptics, antihypertensives, neurotoxins)? Yes No
The number of preventive medications required will depend on your health plan.

Record the names of previous therapies: _____

If patient experienced inadequate response with medication, how long did the trial period last? _____

Did the patient fail because of intolerance or contraindication? Yes No

Common considerations for completing a PA

- Review health plan–specific guidelines for Aimovig™ and ensure you have
 - Your provider ID number
 - Patient insurance information
 - Any necessary documents to support PA, including a copy of your patient’s chart notes
 - Aimovig™ full Prescribing Information
- Complete and sign all documents as required and by plan deadlines
- An additional form is available for reauthorizations

Use this resource to help get through the basics of the PA process.

To submit PAs electronically with enhanced support, consider using CoverMyMeds, available at CoverMyMeds.com

*These criteria are specific to the PA approval process.

†Please see table on back side for examples of drugs within preventive drug classes. Please be sure to record all medications the patient has tried and failed.

Please see accompanying Aimovig™ full Prescribing Information.



List of common preventive therapies¹⁻⁵:

Antidepressants	Antiepileptics	Antihypertensives	Neurotoxins	Other
<input type="checkbox"/> amitriptyline	<input type="checkbox"/> topiramate	<input type="checkbox"/> propranolol	<input type="checkbox"/> botulinum toxin	
<input type="checkbox"/> nortriptyline	<input type="checkbox"/> zonisamide	<input type="checkbox"/> verapamil		
<input type="checkbox"/> fluoxetine	<input type="checkbox"/> divalproex	<input type="checkbox"/> candesartan		
<input type="checkbox"/> paroxetine	<input type="checkbox"/> gabapentin	<input type="checkbox"/> atenolol		
<input type="checkbox"/> venlafaxine	<input type="checkbox"/> lamotrigine	<input type="checkbox"/> metoprolol		
<input type="checkbox"/> duloxetine	<input type="checkbox"/> pregabalin	<input type="checkbox"/> nadolol		
		<input type="checkbox"/> timolol		

List of common acute therapies⁵⁻⁸:

Over-the-counter drugs	Nonsteroidal anti-inflammatory drugs	Triptans	Other
<input type="checkbox"/> ibuprofen	<input type="checkbox"/> ketoprofen	<input type="checkbox"/> sumatriptan	
<input type="checkbox"/> caffeine compounds	<input type="checkbox"/> meloxicam	<input type="checkbox"/> sumatriptan/ naproxen	
<input type="checkbox"/> naproxen	<input type="checkbox"/> diclofenac	<input type="checkbox"/> rizatriptan	
<input type="checkbox"/> acetaminophen	<input type="checkbox"/> celecoxib	<input type="checkbox"/> zolmitriptan	
		<input type="checkbox"/> almotriptan	
		<input type="checkbox"/> naratriptan	
		<input type="checkbox"/> frovatriptan	
		<input type="checkbox"/> eletriptan	



If you need additional help, Aimovig Ally™ is here for you. We can help answer your questions about Aimovig™ and provide resources and support. Contact our Aimovig Ally™ support team at 833-AIMOVIG (833-246-6844), Monday - Friday, 8 am - 8 pm ET

References: 1. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance. *Neuropsychiatr Dis Treat*. 2008;4(6):1155-1167. 2. A research study examining the use of duloxetine in the prevention of migraine headache. US National Library of Medicine. ClinicalTrials.gov website. <https://clinicaltrials.gov/ct2/show/NCT00443352>. Accessed August 15, 2018. 3. Silberstein SD. Preventative migraine treatment. *Continuum*. 2015;21(4):973-989. 4. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012;78(17):1337-1345. 5. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. *Lancet Neurol*. 2010;9(3):285-298. 6. Lipton RB, Diener HC, Robbins MS, Yacoub Garas S, Patel K. Caffeine in the management of patients with headache. *J Headache Pain*. 2017;18(7):1-11. 7. Ng-Mak DS, Hu XH, Chen Y, Ma L. Acute migraine treatment with oral triptans and NSAIDs in a managed care population. *Headache*. 2008;48:1176-1185. 8. What are the acute treatments for migraine and how are they used? Japanese Society of Neurology. *Clinical Practice Guideline for Chronic Headache 2013*. <https://www.neurology-jp.org/guidelinem/ch/documents/part%20II-2.pdf>. Accessed August 15, 2018.

INDICATION

Aimovig™ (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

- The most common adverse reactions in clinical studies (≥ 3% of Aimovig™-treated patients and more often than placebo) were injection site reactions and constipation.

Please see accompanying Aimovig™ full Prescribing Information.

